Integrating emerging AL therapies into real‑world MDT decisions
Listen to our expert faculty discuss multidisciplinary treatment decisions for amyloid light-chain amyloidosis (AL), including cardiac and renal care, treatment tolerability and frailty. They also explore emerging fibril-directed therapies and their potential role alongside plasma-cell–directed treatment, informed by clinical evidence and local approval.
The multidisciplinary team:
Hematologist – Dr. Yawara Kawano, Kumamoto University Hospital, Kumamoto City, Japan
Cardiologist – Dr. Christian Nitsche, Medical University of Vienna, Vienna, Austria
Amyloidosis specialist with a renal focus –…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.